≥18 years of age
Showing 1 - 25 of >10,000
Lymphatic Malformation Trial (TARA-002)
Not yet recruiting
- Lymphatic Malformation
- TARA-002
- (no location specified)
May 22, 2023
Atopic Dermatitis, Eczema Trial (Lebrikizumab, Placebo)
Not yet recruiting
- Atopic Dermatitis
- Eczema
- Lebrikizumab
- Placebo
- (no location specified)
Feb 10, 2023
Diabetes, Type 1 Diabetes, Diabetes type1 Trial in Charlestown (Bacillus Calmette-Guérin, Saline Injection)
Recruiting
- Diabetes Mellitus
- +3 more
- Bacillus Calmette-Guérin
- Saline Injection
-
Charlestown, MassachusettsImmunobiology Labs CNY 149
May 10, 2023
Dengue Trial (V181, Butantan-DV)
Not yet recruiting
- Dengue
- V181
- Butantan-DV
- (no location specified)
Jan 24, 2023
Norovirus Acute Gastroenteritis Trial in United States (mRNA-1403, mRNA-1405, Placebo)
Not yet recruiting
- Norovirus Acute Gastroenteritis
- mRNA-1403
- +2 more
-
Long Beach, California
- +14 more
Aug 7, 2023
Pneumococcal Disease Trial (Candidate-1, Candidate-2, Candidate-3)
Not yet recruiting
- Pneumococcal Disease
- Candidate-1
- +8 more
- (no location specified)
Aug 3, 2022
Traumatic Brain Injury, Cerebral Edema Trial (ABX-101 1mg, ABX-101 2mg)
Not yet recruiting
- Traumatic Brain Injury
- Cerebral Edema
- ABX-101 1mg
- ABX-101 2mg
- (no location specified)
Oct 20, 2023
Pneumococcal Disease Trial in India (13-valent pneumococcal conjugate vaccine)
Completed
- Pneumococcal Disease
- 13-valent pneumococcal conjugate vaccine
-
Surat, Gujarat, India
- +4 more
Jan 10, 2023
COVID-19 Trial in Chongqing, Jinan (Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo)
Active, not recruiting
- COVID-19
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
- Placebo
-
Chongqing, Chongqing, China
- +1 more
Jan 11, 2023
COVID-19 Trial in Barranquilla, Cali (Candidate vaccine, SCB-2019)
Not yet recruiting
- COVID-19
- Candidate vaccine, SCB-2019
-
Barranquilla, Colombia
- +1 more
Aug 23, 2022
Pneumococcal Disease Trial in United States (V116, PPSV23)
Not yet recruiting
- Pneumococcal Disease
- V116
- PPSV23
- (no location specified)
Jul 12, 2022
Sexually Transmitted Diseases Trial in Lenexa (NgG low dose investigational vaccine, NgG medium dose investigational vaccine,
Recruiting
- Sexually Transmitted Diseases
- NgG low dose investigational vaccine
- +5 more
-
Lenexa, KansasGSK Investigational Site
Jan 6, 2023
FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia Trial (midostaurin)
Available
- FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia
- (no location specified)
Oct 18, 2022
Pneumococcal Disease Trial (20-valent pneumococcal conjugate vaccine)
Not yet recruiting
- Pneumococcal Disease
- 20-valent pneumococcal conjugate vaccine
- (no location specified)
May 16, 2023
Influenza, Human Trial (FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A)
Not yet recruiting
- Influenza, Human
- FLU Q-PAN H5N8 Formulation 1
- +3 more
- (no location specified)
Jul 27, 2023
Herpes Zoster Subunit Vaccine During Pregnancy in Adult
Not yet recruiting
- Herpes Zoster
- Data collection
- (no location specified)
Mar 31, 2023
Chronic Spontaneous Urticaria Trial (LOU064 (blinded), )
Not yet recruiting
- Chronic Spontaneous Urticaria
- LOU064 (blinded)
- placebo
- (no location specified)
Dec 23, 2022
Influenza (Healthy Volunteers) Trial in Melbourne, Peoria (mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine)
Recruiting
- Influenza (Healthy Volunteers)
- mRNA NA vaccine
- High Dose Quadrivalent Influenza Vaccine
-
Melbourne, Florida
- +1 more
Jun 29, 2022
Influenza Immunization Trial (Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH)
Not yet recruiting
- Influenza Immunization
- Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
- (no location specified)
Aug 22, 2022
COVID-19 Trial in Wuhan (Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001)
Active, not recruiting
- COVID-19
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
- ZF2001
-
Wuhan, Hubei, ChinaHubei Provincial Center for Disease Control and Prevention
Jan 12, 2023
RESPIRATORY SYNCYTIAL VIRUS (RSV) Trial (RSVpreF 120 µg, RSVpreF 60 µg, )
Not yet recruiting
- RESPIRATORY SYNCYTIAL VIRUS (RSV)
- RSVpreF 120 µg
- +2 more
- (no location specified)
Jun 2, 2023